Additionally, KRAS G12C mutations represent only ~15% of KRAS-mutated cancers, leaving most patients, including those with common mutations such as G12D (frequent in CRC and PDAC), without approved targeted therapies.181 Another challenge is poor blood-brain barrier (BBB) penetration. Here, KRAS is linked to cancer.